央广网北京12月10日消息（记者杜希萌）据中央广播电视总台中国之声报道，昨天（9日）晚上， 国家医保局对新发布的2025年医保药品目录进行解读。新版国家医保药品目录新增114种药品，其中50 种是一类创新药。同时，19种药品纳入首版商保创新药目录。谈判成功的药品为何能获得青睐？医保目 录内药品持续上新，又给患者看病用药带来哪些影响？ 而今年首次开谈的商业健康保险创新药品目录同样把药物创新程度和临床价值作为最关键的考虑因 素。黄心宇说，今年共收到了141个商保创新药目录的申报信息，最终有121种药品通过了形式审查，而 在专家评审阶段，通过审查的药品数量仅有24种，并最终有19种药品协商成功被纳入商保创新药目录。 从141个到19个，被纳入目录的药品均是创新程度极高、临床价值特别大的药品，且在基本医保目录保 障中目前仍属空白。 黄心宇说："纳入商业保险创新药目录的19种药品中，一类新药有9种，约占50％；新增CAR-T等T 细胞治疗药品、戈谢病、短肠综合征、神经母细胞瘤等罕见病治疗药品，填补基本医保目录保障空白； 目录内多为新机制、新靶点药品，与基本医保目录错位发展、互为补充；推荐商业健康保险、医疗互助 等多层次 ...

Investment Rating - The industry investment rating is "Outperform the Market" with an expectation of over 10% relative increase in the industry index compared to the market in the next six months [5][10]. Core Insights - The new medical insurance drug list has been released, adding 50 first-class innovative drugs. A total of 114 new drugs were added, with a success rate of 88%, higher than last year's 76%. The total number of drugs in the list has increased to 3,253, including 1,857 Western medicines and 1,396 traditional Chinese medicines. This new list will be implemented starting January 1, 2026 [3]. - The first commercial health insurance innovative drug list has been published, including 19 drugs from 18 pharmaceutical companies, covering treatments for cancer, rare diseases, and Alzheimer's disease. These drugs are not included in the medical insurance fund payment scope, promoting the development of a multi-tiered medical security system and increasing accessibility to high-value innovative drugs [4]. - The collaboration between the new medical insurance drug list and the commercial health insurance innovative drug list aims to create a new payment structure for innovative drugs, addressing the affordability issue for patients and providing a sustainable return mechanism for pharmaceutical companies, thus driving high-quality development in China's innovative drug industry [4]. Summary by Sections - **New Medical Insurance Drug List**: 50 first-class innovative drugs added, total drugs increased to 3,253, with a record number of 69 innovative drugs approved for market entry this year [3]. - **Commercial Health Insurance Drug List**: 19 innovative drugs included, enhancing accessibility and complementing the basic medical insurance system [4]. - **Policy Impact**: The synergy between the two lists is expected to accelerate the development of China's innovative drug research and create a robust engine for high-quality growth in the industry [4].

转自：新华财经 •2025年医保商保"双目录"发布 114种新药成功纳入医保 50种为一类创新药 •11月末外储规模小幅回升 黄金储备实现"十三连增" •百度回应旗下AI芯片公司上市计划：正就昆仑芯拟分拆上市进行评估 •国家医保局、人力资源社会保障部印发《国家基本医疗保险、生育保险和工伤保险药品目录》以及《商业健康保险创新药品目录》。其中提到，各地医保 部门要会同有关部门推动多层次医疗保障体系建设，积极支持普惠型商业健康保险发展，商保创新药目录推荐商业健康保险、医疗互助等多层次医疗保障体 系参考使用。支持商保机构根据商保创新药目录设计新产品、更新赔付范围、调整赔付方式，更好满足患者用药需求，切实减轻患者医疗费用负担。鼓励有 条件的地区探索开展医保、工伤保险与商保"一站式"结算。各地医保部门和人力资源社会保障部门应建立医保目录内药品配备和使用情况监测机制。（新华 财经） •据国家医保局，2025年国家医保药品目录成功新增114种药品，有50种是一类创新药，总体成功率88%，较2024年的76%明显提高。19种药品纳入首版商保 创新药目录，包括CAR-T等肿瘤治疗药品，也有神经母细胞瘤、戈谢病等罕见病治疗药品，还 ...

【导读】114种药品新增进入2025年国家医保药品目录，19种药品进入商保创新药目录 中国基金报记者 王思文 12月7日，2025年药品目录谈判协商结果在广州发布，市场关注的新版基本医保药品目录和首版《商业健康保险创新药品目录》正式公布。今年是国家医 保药品目录连续第八年进行调整。 新版药品目录自2026年1月1日起正式执行，《国家基本医疗保险、工伤保险和生育保险药品目录（2024年）》（医保发〔2024〕33号）同时废止。 首版商保创新药目录发布 18家企业19种药品被纳入 首次增设商保创新药目录是2025年医保目录调整的重要突破，也是市场关注焦点。 被纳入首版商保创新药目录的19种药品中，既有CAR-T等肿瘤治疗药品，也有神经母细胞瘤、戈谢病等罕见病治疗药品，还有阿尔茨海默病治疗药品等。 2025年版国家医保+商保药品目录正式发布 根据国家医保局对外发布的2025年版国家基本医疗保险、生育保险和工伤保险药品目录和首版商业健康保险创新药品目录显示，2025年国家医保药品目录 成功新增114种药品，19种药品被纳入首版商保创新药目录。 在本次目录调整的新增药品中，有50种是一类创新药，总体成功率为88%，较2 ...

Core Points - The 2025 National Medical Insurance Drug List has been officially released, adding 114 new drugs, with 19 drugs included in the first Commercial Health Insurance Innovative Drug List [1][4] - This marks the eighth consecutive year of adjustments to the National Medical Insurance Drug List [1] Group 1: National Medical Insurance Drug List - The new drug list will take effect from January 1, 2026, replacing the 2024 version [3] - The total number of drugs in the National Medical Insurance Drug List has increased to 3,253, including 1,857 Western medicines and 1,396 traditional Chinese medicines [5] - The inclusion of 50 innovative drugs in this adjustment reflects an overall success rate of 88%, up from 76% in 2024 [5] - The updated list enhances coverage for critical areas such as cancer, chronic diseases, rare diseases, and pediatric medications [5] - Local authorities are required to strictly implement the new drug list and update their information systems accordingly [5] Group 2: Commercial Health Insurance Innovative Drug List - The first Commercial Health Insurance Innovative Drug List is a significant breakthrough in the 2025 drug list adjustments [7] - The 19 drugs included in this list cover treatments for various conditions, including CAR-T therapies for cancer and treatments for rare diseases like neuroblastoma and Gaucher disease [8] - The National Medical Insurance Bureau emphasizes the need to promote the use of drugs listed in the Commercial Health Insurance Innovative Drug List and integrate them into commercial health insurance coverage [8]

北京商报讯（记者 李秀梅）12月7日，新华社消息，2025年国家医保药品目录及首版商保创新药目录在 广州发布。纳入首版商保创新药目录的19种药品中，既有CAR-T等肿瘤治疗药品，也有神经母细胞瘤、 戈谢病等罕见病治疗药品，还有阿尔茨海默病治疗药品等。 ...

北京商报讯（记者 丁宁）12月7日，2025年国家医保药品目录及首版商保创新药目录在广州发布。据了 解，19种药品纳入首版商保创新药目录。纳入首版商保创新药目录的19种药品中，既有CAR-T等肿瘤治 疗药品，也有神经母细胞瘤、戈谢病等罕见病治疗药品，还有阿尔茨海默病治疗药品等。 ...